Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of YZJ-1139 Tablets in the Treatment of Insomnia Disorder

NCT05525637 is registered in ClinicalTrials.gov with Shanghai Haiyan Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT05525637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05525637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of YZJ-1139 Tablets in the Treatment of Insomnia Disorder
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 17, 2021
Completion date
September 27, 2023
Enrollment
1,037 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia disorder